EIQ Echo IQ Limited

Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia. It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, including aortic stenosis, diastolic dysfunction, and heart failure. The company has a research collaboration with Mayo Clinic to evaluate echo IQ's proprietary artificial intelligence platform for cardiac risk stratification in oncology patients. The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021. Echo IQ Limited is headquartered in Sydney, Australia.